Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study

BACKGROUND: Structure-based drug design (SBDD) can provide valuable guidance to drug discovery programs. Robust construct design and expression, protein purification and characterization, protein crystallization, and high-resolution diffraction are all needed for rapid, iterative inhibitor design. W...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Argiriadi, Maria A, Sousa, Silvino, Banach, David, Marcotte, Douglas, Xiang, Tao, Tomlinson, Medha J, Demers, Megan, Harris, Christopher, Kwak, Silvia, Hardman, Jennifer, Pietras, Margaret, Quinn, Lisa, DiMauro, Jennifer, Ni, Baofu, Mankovich, John, Borhani, David W, Talanian, Robert V, Sadhukhan, Ramkrishna
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: BioMed Central 2009
Θέματα:
Research Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2678131/
https://ncbi.nlm.nih.gov/pubmed/19296855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6807-9-16
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια